ARTICLES| VOLUME 22, ISSUE 4, P483-495, APRIL 01, 2022 Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials Gang Zeng, Qianhui Wu, Hongxing Pan, et al Lancet Infect Dis 2022; 22: 483-495 Summary Background Large-scale vaccination against COVID-19 is being implement...

ARTICLES| VOLUME 399, ISSUE 10335, P1618-1624, APRIL 23, 2022 Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study Cristina Menni, Ana M Valdes, Lorenzo Polidori, et al Lancet 2022; 399: 1618-1624 Summary Background The SARS-CoV-2 variant of concern, omicron, appears to be less se...

ARTICLES|ONLINE FIRST Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial Deepali Kumar, Michael G Ison, Jean-Paul Mira, et al Lancet Infect Dis Published:January 24, 2022 DOI:https://doi.org/10.1016/S1473-3099(21)00469-2 Summary Background Neuraminidase inhibitors (NAIs) are considered th...

ORIGINAL ARTICLE Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting Ori Magen, Jacob G. Waxman, Maya Makov-Assif, et al N Engl J Med April 13, 2022DOI: 10.1056/NEJMoa2201688 Abstract BACKGROUND With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine,...

ARTICLES|ONLINE FIRST Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalised adults with bloodstream infections: a multicentre, prospective, cohort study Evelina Tacconelli, Siri Göpel, Beryl P Gladstone, et al Lancet Infect Dis Published:January 19, 2022 DOI:https://doi.org/10.1016/S1473-3099(21)00587-9 Summary Background The burden of bloodstream infections remains high worldwide and cannot be confine...

ORIGINAL ARTICLE BNT162b2 Protection against the Omicron Variant in Children and Adolescents Ashley M. Price, Samantha M. Olson, Margaret M. Newhams, et al N Engl J Med March 30, 2022DOI: 10.1056/NEJMoa2202826 Abstract BACKGROUND Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion...

ARTICLES| VOLUME 22, ISSUE 2, P274-283, FEBRUARY 01, 2022 Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial Valentijn A Schweitzer, Inger van Heijl, Wim G Boersma, et al Lancet Infect Dis 2022; 22: 274-283 Summary Background Adults hospitalised to a non-intensive care unit (ICU) ward wit...

ORIGINAL ARTICLE Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia David J. Kuter, Merlin Efraim, Jiri Mayer, et al N Engl J Med 2022; 386:1421-1431DOI: 10.1056/NEJMoa2110297 Abstract BACKGROUND Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton’s tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)–mediated platelet de...

ORIGINAL ARTICLE Early Outpatient Treatment for Covid-19 with Convalescent Plasma David J. Sullivan, Kelly A. Gebo, Shmuel Shoham, et al N Engl J Med March 30, 2022DOI: 10.1056/NEJMoa2119657 Abstract BACKGROUND Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain. ...

ARTICLES|ONLINE FIRST Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis Willis S Bowman, Chad A Newton, Angela L Linderholm, et al Lancet Respir Med Published:January 18, 2022 DOI:https://doi.org/10.1016/S2213-2600(21)00503-8 Summary Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to...